ORIGINAL RESEARCH article
Front. Med.
Sec. Intensive Care Medicine and Anesthesiology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1464071
Effects of continuous glucose monitoring in enhanced recovery after colorectal cancer patient surgery with type 2 diabetes (Application of CGM in the ERAS process of CRC patient with diabetes)
Provisionally accepted
- The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: This study aimed to evaluate the impact of Continuous Glucose Monitoring (CGM) on enhanced recovery after surgery (ERAS) outcomes in colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM).We conducted an observational cohort study of adult patients (≥18 years) with T2DM undergoing abdominal surgery for pathologically confirmed CRC.Exclusion criteria included history of other malignancies, preoperative infections, or incomplete clinical data. Participants were stratified into two groups: the exposed group (CGM monitoring) and the control group (conventional glucose analyzer [CGA]). Primary outcomes included glycemic variability, surgical complications, ERAS milestones, and patient satisfaction scores. Results: Among 181 enrolled patients (CGM=81, CGA=100), CGM demonstrated superior glycemic control compared to CGA, with significantly lower mean daily glucose levels at postoperative day 1 (9.52±2.53 vs 10.37±2.26 mmol/L, p<0.05) and day 3 (9.36±1.82 vs 10.64±1.84 mmol/L, p<0.05). The CGM group showed better clinical outcomes including improved anastomotic healing (p<0.05), shorter time to first flatus (p<0.05), and reduced length of hospitalization (p<0.05). Patient satisfaction scores were significantly higher in the CGM group (32.42±3.33 vs 29.81±2.98, p<0.05). Conclusions: CGM provides superior perioperative glucose monitoring in diabetic CRC patients, particularly during the critical 72-hour postoperative period. The technology facilitates early detection of acute hyperglycemia, promotes wound healing, and accelerates recovery within ERAS protocols. These findings support the clinical value of CGM implementation in surgical management of T2DM patients with CRC.
Keywords: Continuous glucose monitoring, colorectal cancer, diabetes, Surgery, Eras
Received: 23 Dec 2024; Accepted: 14 Apr 2025.
Copyright: © 2025 Wang, Zhou, Wang, Ou, Wu, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hua Li, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.